GLP-1 Medications for Binge Eating Disorder: What the Research Shows

Key Points

• No large dedicated randomized trials exist yet for GLP-1s specifically in binge eating disorder
• Preliminary evidence from subgroup analyses and qualitative studies is promising
• GLP-1s reduce food preoccupation, emotional eating, and binge triggers
• These medications work best when combined with therapy addressing psychological aspects of binge eating
• The neurobiological effects on reward pathways may be as important as appetite suppression
• Clinical use is currently off-label but increasingly common based on emerging data

Binge eating disorder is the most common eating disorder, affecting millions of people. It’s also one of the most frustrating conditions to treat because standard approaches often don’t work that well.

I’ve worked with many patients struggling with binge eating. They’ve usually tried multiple therapies, various medications, countless attempts at dietary control. Some things help temporarily, but the binge episodes keep returning. The shame and hopelessness that develop after repeated treatment failures are heartbreaking.

So when early data started emerging that GLP-1 medications might help with binge eating, I paid close attention. Not because I thought we’d found a magic cure. But because we desperately need more effective options for this difficult-to-treat condition.

Now, I need to be upfront about something. The research on GLP-1 medications specifically for binge eating disorder is still preliminary. We don’t have large, dedicated randomized controlled trials yet. What we have is exploratory analyses from weight loss studies, small qualitative studies, and accumulating clinical experience.

But what we’re seeing is interesting enough that many clinicians, including me, are using these medications for carefully selected patients with binge eating disorder. And in my experience, they can be genuinely helpful when used as part of comprehensive treatment.

Let me walk you through what the research actually shows, what my clinical experience has been, and how to think about whether this approach might be appropriate for someone struggling with binge eating.

What Is Binge Eating Disorder? (Quick Review)

Before diving into GLP-1s, let me clarify what we’re talking about.

Binge eating disorder involves recurrent episodes of eating large amounts of food, usually rapidly, often to the point of physical discomfort. These episodes are accompanied by a sense of loss of control. You feel like you can’t stop eating even if you want to.

What makes it a disorder rather than just occasional overeating is the frequency (at least once a week for three months), the distress it causes, and the characteristic features. Eating when not physically hungry. Eating alone due to embarrassment. Feeling disgusted, depressed, or guilty after binge episodes.

Importantly, unlike bulimia nervosa, binge eating disorder doesn’t involve compensatory behaviors like purging or excessive exercise. The binges happen, cause immense distress, and then repeat in a painful cycle.

Many people with binge eating disorder are overweight or obese, though not all. The disorder can occur at any weight. But the combination of binge eating disorder and obesity is particularly common and particularly difficult to treat.

The psychological aspects are crucial. Emotional eating in response to stress, anxiety, depression, or loneliness. Using food to cope with difficult feelings. Dieting attempts that trigger restriction-binge cycles. Body image distress. Often a history of trauma or adverse experiences.

Standard treatment includes cognitive behavioral therapy specifically designed for binge eating (CBT-ED), which helps about 40-60% of people achieve binge abstinence. Medications like certain antidepressants and lisdexamfetamine (Vyvanse, the only FDA-approved medication for binge eating disorder) can help but don’t work for everyone.

We need more options. That’s why the potential of GLP-1 medications is so interesting.

What the Research Actually Shows (And Doesn’t Show)

Let me be really clear about the current state of evidence, because I don’t want to overstate what we know.

There are no large, dedicated randomized controlled trials of GLP-1 receptor agonists specifically for binge eating disorder. This is a significant gap. The kind of robust evidence we’d need for FDA approval doesn’t exist yet.

What we do have is promising preliminary data from several sources.

Subgroup analyses from weight loss trials. The STEP 5 trial was a large study of semaglutide 2.4 mg for weight management. A subgroup analysis looked at 174 adults with obesity who also had issues with eating control and food cravings.

Over 104 weeks, participants on semaglutide showed significant improvements in control of eating, reduced cravings for both savory and sweet foods, and decreased eating-related psychopathology compared to placebo. The improvements correlated with weight loss but appeared to involve more than just eating less due to reduced appetite.

This wasn’t specifically a binge eating disorder population, but many of these participants likely had binge eating patterns even if not formally diagnosed.

Exploratory analyses from behavioral intervention studies. Another study looked at liraglutide 3.0 mg combined with intensive behavioral therapy in 150 adults with obesity. At 24 weeks, the liraglutide group showed greater reductions in dietary disinhibition, global eating disorder psychopathology, and binge eating compared to behavioral therapy alone.

Interestingly, by 52 weeks, the differences between groups were no longer statistically significant. This raises questions about long-term effectiveness or whether the benefits are mainly during active weight loss.

Qualitative studies providing rich detail. A qualitative study interviewed eight patients with both obesity and binge eating disorder who were treated with liraglutide. The findings were really interesting.

Participants described reduced food preoccupation. They weren’t constantly thinking about food anymore. When binge triggers occurred (stress, difficult emotions, social situations), the urge to binge was less intense. Some described feeling like they had more control and could pause before acting on urges.

They reported improved emotional wellbeing beyond just reduced binge eating. Feeling less dominated by food. Less shame. More hope that change was possible.

But this was a small qualitative study without a control group, so we can’t draw firm conclusions. Still, the detailed descriptions of people’s experiences are valuable and consistent with what I hear clinically.

Preclinical research on mechanisms. Animal studies show that GLP-1 receptor agonists affect brain reward pathways involved in food reward and motivation to eat. They appear to reduce the rewarding value of highly palatable foods without just making animals sick or nauseated.

This is important because it suggests these medications might be working through reward system modulation, not just appetite suppression. That’s potentially very relevant for binge eating, which involves dysregulated reward processing.

The evidence gaps are real. We don’t have large trials with formally diagnosed binge eating disorder patients as the primary population. We don’t have validated binge eating-specific outcome measures in most studies. We don’t have long-term data on durability of benefits specifically for binge eating.

These gaps mean GLP-1s are not FDA-approved for binge eating disorder. Use in this population is off-label. We’re making clinical decisions based on preliminary but promising data, not definitive evidence.

How GLP-1 Medications Might Help Binge Eating (The Mechanisms)

Understanding how these medications might work for binge eating helps clarify when they might be useful and how to use them best.

They reduce food reward and craving. This appears to be mediated by effects on brain reward pathways. GLP-1 receptors exist in areas like the nucleus accumbens and ventral tegmental area, which are central to reward processing.

When GLP-1 medications activate these receptors, they appear to reduce the rewarding value of food, particularly highly palatable foods high in sugar and fat. These are exactly the foods people typically binge on.

People describe it as reducing “food noise.” The constant mental chatter about food quiets down. Cravings feel less intense and urgent. This doesn’t mean zero desire for food, but the obsessive quality decreases.

For someone with binge eating disorder, this could break the cycle where obsessive food thoughts build until they culminate in a binge episode.

They affect emotional eating differently than appetite. This is important. GLP-1s don’t just make you less hungry in general. They seem to specifically reduce eating in response to emotions, stress, or external cues rather than physical hunger.

Research shows decreases in emotional eating and disinhibited eating. People eat less when they’re stressed, anxious, or bored. They’re better able to stop eating when they’ve had enough.

This targets a core feature of binge eating disorder, where eating is often driven by emotions rather than hunger.

They slow down eating speed and increase awareness. GLP-1 medications slow gastric emptying. You feel full faster and stay full longer. But there may also be effects on eating pace and awareness.

When you eat more slowly, you have more time to register fullness signals. You’re more aware of what you’re eating. This increased awareness can help interrupt the automatic, dissociated quality that often characterizes binge episodes.

They may reduce impulsivity around food. Some research suggests GLP-1s affect executive function and impulse control. If binge eating involves impulsive behavior around food, improving impulse control could help.

This is preliminary, and we need more research on cognitive effects. But clinically, some patients describe feeling more able to pause and make deliberate choices rather than acting on impulses immediately.

They address the obesity that often accompanies binge eating. Many people with binge eating disorder are overweight or obese. The weight itself can worsen psychological distress, increase stigma, and make binge eating feel even more shameful.

By helping with weight management, GLP-1s might reduce some of the distress that perpetuates binge eating. This isn’t the primary mechanism, but it’s not irrelevant either.

My Clinical Experience: What I’ve Seen Work

I’ve prescribed low-dose GLP-1 medications for quite a few patients with binge eating disorder over the past couple of years. Always as part of comprehensive treatment including therapy. Always off-label, with clear discussion about the evidence gaps.

Here’s what I’ve observed.

Many patients report significant reduction in binge episodes. Not everyone, but many. The frequency of binges decreases. When binges do occur, they’re often less severe, less prolonged, and recovery feels quicker.

Some patients achieve complete binge abstinence while on the medication combined with therapy. Others reduce from daily binges to once or twice a week. Any reduction is meaningful given how distressing binge eating is.

The change in food preoccupation is often dramatic. This is what patients comment on most. “I’m not thinking about food constantly anymore.” “The obsession with what I’m going to eat next just isn’t there like it was.”

This cognitive shift seems to happen fairly quickly, often within the first few weeks of starting the medication. It creates mental space for working on other things in therapy.

Emotional eating specifically decreases. Patients report that when they’re stressed or upset, they don’t automatically turn to food like they used to. They have a moment where they can pause and choose a different response.

This doesn’t mean they never eat emotionally. But the automatic nature of it decreases. There’s more space between the emotion and the eating behavior.

The medication works best with concurrent therapy. I haven’t seen good outcomes when GLP-1s are used alone without psychological treatment. The medication helps with the biological and reward aspects, but it doesn’t address the underlying psychological factors, relationship patterns, trauma, or emotional regulation skills.

When combined with good therapy that addresses these elements, the medication seems to make the therapy more effective. The reduced food preoccupation and decreased urge intensity create space for the therapeutic work to happen.

Lower doses often work well. I typically start with very low doses and increase slowly. Many patients do well at doses below what would be used for weight loss alone. We’re not trying to maximally suppress appetite. We’re trying to take the edge off the obsessive quality and intense urges while still allowing normal eating.

Side effects are usually manageable. With low-dose titration, most patients have minimal nausea. Some have none. When side effects do occur, they’re usually manageable and improve over time.

I’m careful with patients who have binge eating disorder because they often have complicated relationships with feeling hungry or full. We want to reduce binge urges, not create new anxiety about eating or inability to eat adequate nutrition.

Not everyone responds. Some patients try a GLP-1 and don’t find it helpful for their binge eating. The medication doesn’t reduce urges enough to make a difference. Or side effects are problematic. Or they just don’t like how it makes them feel.

That’s okay. These medications aren’t right for everyone, and we have other options to try.

Who Might Benefit? Patient Selection Considerations

Given that we’re using these medications off-label based on preliminary evidence, thoughtful patient selection is important.

Good candidates in my experience:

Patients with binge eating disorder and obesity. The combination is common, and both conditions can be addressed simultaneously with GLP-1s.

Patients who describe intense food cravings and preoccupation. If obsessive food thoughts are a prominent feature, GLP-1s seem more likely to help.

Patients with significant emotional eating. If eating in response to stress, anxiety, or depression is a major driver of binge episodes, GLP-1s’ effects on emotional eating could be particularly useful.

Patients who’ve tried therapy alone without sufficient improvement. If someone has had good CBT for binge eating but still struggles significantly, adding a medication makes sense.

Patients with binge eating disorder who aren’t significantly underweight. These medications reduce appetite and shouldn’t be used in anyone who needs to gain weight or is at risk of becoming underweight.

Patients willing to engage in therapy alongside medication. The medication alone isn’t sufficient treatment for the psychological aspects of binge eating disorder.

Patients where I’m more cautious:

Anyone with a history of restrictive eating disorders like anorexia nervosa. Medications that reduce appetite could trigger or worsen restriction.

Patients with severe purging behaviors. Binge eating disorder by definition doesn’t include compensatory behaviors, but if someone has both binge eating and purging, we need to address the purging first.

Patients with very chaotic eating patterns where it’s hard to distinguish binges from general irregular eating. These medications work better when there’s a clear pattern of binge episodes we’re trying to reduce.

Patients who can’t afford the medication or access it consistently. Starting a medication that helps but then having to stop due to cost creates its own problems.

Patients with contraindications to GLP-1 medications generally (personal or family history of medullary thyroid carcinoma, history of pancreatitis, pregnancy).

Combining Medication with Therapy: The Essential Partnership

I can’t emphasize this enough. GLP-1 medications for binge eating disorder should not be used without concurrent psychological treatment.

Why therapy is essential:

Binge eating disorder has significant psychological components that medication doesn’t address. Emotional regulation difficulties. Relationship between eating and self-worth. Body image distress. Trauma histories. Interpersonal problems. These need psychological treatment.

The medication can make therapy more effective by reducing the biological urgency around food, creating mental space for psychological work. But the psychological work still needs to happen.

Skills need to be developed. Alternative coping strategies for difficult emotions. Mindfulness around eating. Challenging distorted thoughts about food and body. Building self-compassion. These skills support long-term recovery even if medication is eventually discontinued.

What therapy should include:

Cognitive behavioral therapy adapted for binge eating (CBT-ED) has the strongest evidence base. This involves identifying triggers, challenging thoughts that maintain binge eating, developing alternative responses to urges, and building more balanced eating patterns.

Dialectical behavior therapy (DBT) skills can be very helpful, particularly emotion regulation and distress tolerance skills. Many people with binge eating disorder need these skills.

Trauma work if relevant. Many people with binge eating disorder have trauma histories. Sometimes the binge eating is partially a response to unresolved trauma. Addressing the trauma can be important for recovery.

Nutritional counseling from someone who understands eating disorders. Not rigid meal plans or restriction, but gentle guidance toward more balanced eating that supports physical and mental health.

The medication supports the therapy by:

Reducing the obsessive quality of food thoughts that can dominate attention and interfere with focusing on other therapeutic work.

Decreasing urge intensity enough that people can practice using coping skills before the urge becomes overwhelming.

Providing some success experiences with reducing binge eating, which builds hope and motivation for continuing treatment.

Creating a neurobiological environment where new habits and patterns are easier to establish.

But again, the medication is supporting therapy, not replacing it.

Practical Considerations: How I Use GLP-1s for Binge Eating

Here’s my typical approach when considering a GLP-1 medication for someone with binge eating disorder.

Comprehensive assessment first. I need to understand the full picture. How often are binge episodes occurring? What triggers them? What maintains them? What’s the emotional context? Any trauma history? What’s been tried before? Current eating patterns overall? Physical health status including metabolic markers?

I also assess for other eating disorder features. Any restriction or food avoidance between binges? Body image concerns? Other compensatory behaviors? These affect treatment planning.

Ensure therapy is in place or starting. I won’t prescribe a GLP-1 for binge eating disorder without concurrent psychological treatment. Either I’m providing therapy myself, or I have a clear plan for therapy with another provider I trust.

Start with very low doses. For semaglutide, I might start at 0.25 mg once weekly and increase slowly over many weeks. I’m not in a rush to get to high doses. The goal is finding the lowest dose that reduces binge urges and food preoccupation without causing problematic side effects or excessive appetite suppression.

Many patients do well at 0.5 mg or 1 mg weekly, well below the 2.4 mg used in weight loss trials. We’re not maximally suppressing appetite. We’re modulating the reward system and reducing obsessive food thoughts.

Monitor closely. Weekly or every-other-week check-ins initially. How are binge episodes? How’s food preoccupation? Any side effects? How’s mood? Are they able to eat adequate nutrition? How’s the therapy going?

I’m watching for any signs of developing restriction or anxiety about eating. GLP-1 medications reduce appetite, and in someone with binge eating disorder, we need to ensure this doesn’t flip into the opposite problem.

Combine with nutritional support. Working with a dietitian who understands both obesity and eating disorders is valuable. Help establishing regular eating patterns. Ensuring adequate nutrition despite reduced appetite. Addressing any remaining problematic food rules or behaviors.

Plan for the long term. How long should someone stay on a GLP-1 for binge eating disorder? We don’t know. The evidence isn’t there yet to guide duration of treatment.

My approach is to continue as long as it’s helping and well-tolerated. Some patients might eventually taper off after establishing good recovery and skills. Others might benefit from longer-term treatment. These decisions are individualized.

Address access and cost issues proactively. As we discussed in the previous article, cost is a major barrier. I help patients navigate insurance coverage, consider patient assistance programs, or sometimes use compounded versions when necessary and with appropriate safeguards.

Starting a medication that helps significantly and then having to stop because of cost is really difficult. I try to have a plan for sustainable access before starting.

What About Weight Loss?

This is tricky territory. Many people with binge eating disorder and obesity want to lose weight. That’s understandable. But focusing primarily on weight loss can worsen binge eating disorder.

When treating binge eating disorder, binge abstinence is the primary goal, not weight loss. If weight loss happens as a result of stopping binge eating, that’s fine. But making weight loss the main focus often backfires.

Here’s the dilemma with GLP-1s. These medications do cause weight loss. That’s one of their primary effects. For someone with binge eating disorder, is that helpful or potentially harmful?

My approach is to frame it as addressing both the binge eating and the obesity as health concerns, without making weight the measure of success. We track binge frequency, food preoccupation, emotional eating, quality of life, how they’re feeling. Weight is one data point among many, not the primary outcome.

If someone loses weight while on a GLP-1 for binge eating disorder, we pay attention to whether the weight loss is happening in a healthy way (from reduced binge eating and more balanced overall eating) or an unhealthy way (from restriction or inability to eat adequately).

The low-dose approach helps here. We’re not trying to maximally suppress appetite for maximum weight loss. We’re trying to reduce binge eating while maintaining adequate nutrition and healthy relationship with food.

The Bigger Context: Part of Integrated Treatment

Within the functional medicine framework I practice, GLP-1 medications for binge eating disorder are one component of addressing the multiple factors that contribute to the condition.

I’m also thinking about inflammation, because we know inflammation affects mood, impulse control, and eating behavior. Addressing inflammatory triggers through diet and other interventions supports recovery.

I’m assessing for nutrient deficiencies that might affect mood and brain function. Optimizing those can help with the emotional regulation difficulties that often drive binge eating.

I’m addressing sleep, because poor sleep worsens impulse control and emotional regulation. Getting sleep right makes everything else easier.

I’m looking at stress and helping develop stress management skills, because stress is a major trigger for binge eating.

I’m thinking about gut health, because there are emerging connections between gut microbiome and eating behavior, mood, and reward processing.

The GLP-1 medication is supporting all of this work by reducing the biological urgency around food and modulating reward system function. But all the other pieces matter too.

What the Future Holds: Research We Need

The field needs several things to move forward with GLP-1s for binge eating disorder.

Large, dedicated randomized controlled trials in patients with formally diagnosed binge eating disorder using validated binge eating outcome measures. These trials should be long enough to assess durability of benefits, typically at least a year or more.

Head-to-head comparisons with existing treatments like CBT-ED or lisdexamfetamine to understand how GLP-1s compare to and potentially complement other effective interventions.

Studies examining different doses to identify optimal dosing specifically for binge eating, which might differ from optimal dosing for weight loss or diabetes.

Research on who responds best to identify predictors of response. Which patients benefit most? Are there biological or psychological characteristics that predict good response?

Long-term safety and effectiveness data in eating disorder populations specifically. Can people maintain binge remission? What happens if medication is discontinued? Are there any unique risks in this population?

Mechanistic studies clarifying how these medications affect reward processing, emotional eating, and eating disorder psychopathology at a neurobiological level.

Several trials are likely underway now. Results will emerge over the next few years. The evidence base will improve. But while we’re waiting for that research, people are suffering from binge eating disorder now and need treatment.

My Take: Cautiously Optimistic

I’m cautiously optimistic about GLP-1 medications for binge eating disorder based on the preliminary evidence and my clinical experience.

They’re not a cure. They don’t work for everyone. They need to be combined with therapy. The evidence base needs to be stronger. These are all true.

But for some patients, when used thoughtfully as part of comprehensive treatment, they’ve been genuinely helpful. Reducing binge frequency, decreasing food obsession, creating space for psychological work, improving quality of life.

I wish we had better options for binge eating disorder. I wish I had perfect treatments that worked for everyone. I don’t. So I use the tools available, including emerging ones like GLP-1s, as thoughtfully and carefully as I can.

If you’re struggling with binge eating disorder and wondering whether a GLP-1 medication might help, talk with a provider who understands both the medications and eating disorders. Make sure therapy is part of the plan. Go in with realistic expectations about what medication can and can’t do.

This isn’t going to instantly fix the psychological pain or heal the relationship difficulties or resolve the trauma that might be underlying the binge eating. But it might help enough with the biological and reward aspects to make the therapeutic work more possible.

In the next article, we’ll explore one of the most exciting emerging applications of GLP-1 medications: substance use disorders, particularly alcohol use disorder. The research here is newer but potentially practice-changing.

References

1. Bartel S, McElroy SL, Levangie D, Keshen A. Use of Glucagon-Like Peptide-1 Receptor Agonists in Eating Disorder Populations. The International Journal of Eating Disorders. 2024;57(2):286-293. doi:10.1002/eat.24109.
   
2. Balantekin KN, Kretz MJ, Mietlicki-Baase EG. The Emerging Role of Glucagon-Like Peptide 1 in Binge Eating. The Journal of Endocrinology. 2024;262(1):e230405. doi:10.1530/JOE-23-0405.
   
3. Følling IS, Reigstad SL, Hyldmo ÅA, Helvik AS. Patient Experiences With Liraglutide for Obesity and Binge Eating Disorder-a Qualitative Study. PloS One. 2025;20(10):e0335806. doi:10.1371/journal.pone.0335806.
   
4. Wharton S, Batterham RL, Bhatta M, et al. Two-Year Effect of Semaglutide 2.4 mg on Control of Eating in Adults With Overweight/Obesity: STEP 5. Obesity. 2023;31(3):703-715. doi:10.1002/oby.23673.
   
5. Chao AM, Wadden TA, Walsh OA, et al. Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology. Obesity. 2019;27(12):2005-2010. doi:10.1002/oby.22653.
   
6. Pierret ACS, Mizuno Y, Saunders P, et al. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(7):643-653. doi:10.1001/jamapsychiatry.2025.0679.
   
7. Sa B, Maristany A, Subramaniam A, et al. Psychiatric Effects of GLP-1 Receptor Agonists: A Systematic Review of Emerging Evidence. Diabetes, Obesity & Metabolism. 2025;. doi:10.1111/dom.70198.
   
8. Bucciarelli L, Cimino V, Dell’Osso B, Fiorina P. Psychotropic Effects of GLP-1R Agonists. Pharmacological Research. 2025;:108036. doi:10.1016/j.phrs.2025.108036.
   
9. Guo J, Hayes MR, Leggio L, Oru E, Rinaman L. GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders. The Journal of Neuroscience. 2025;45(46):e1375252025. doi:10.1523/JNEUROSCI.1375-25.2025.
   
10. Carminati M, Tondello M, Concina A, Olgiati P, Zanardi R. Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Through the Lens of Psychiatry: A Systematic Review of Potential Benefits and Risks. International Clinical Psychopharmacology. 2025;:00004850-990000000-00170. doi:10.1097/YIC.0000000000000595.